References

1. Abdalian, R, Dhar, P, Jhaveri, K, et al. Prevalence of sclerosing cholangitis in adults with autoimmune hepatitis: evaluating the role of routine magnetic resonance imaging. Hepatology 2008; 47:949.

2. Abdo AA, Bain VG, Kichian K, Lee SS. Evolution of autoimmune hepatitis to primary sclerosing cholangitis: a sequentialsyndrome. Hepatology 2002;36(6):1393–1399

3. Abu-Elamgd, k, Demetris, J, Rakela, J, et al. Transplantation for primary biliary cirrhosis: Recurrence and outcome in 421 patients (abstract). Hepatology 1997; 26:176A.

4. Abdulkarim, AS, Petrovic, LM, Kim, WR, et al. Primary biliary cirrhosis: antinfectious disease caused by Chlamydia pneumoniae? J Hepatol 2004; 40:380.

5. Agarwal K, Czaja AJ, Jones DE, Donaldson PT. Cytotoxic Tlymphocyte antigen-4 (CTLA-4) gene polymorphisms and susceptibility to type 1 autoimmune hepatitis. Hepatology 2000;31(1):49–53

6. AHRENS EH, Jr, PAYNE, MA, KUNKEL, HG, et al. Primary biliary cirrhosis. Medicine (Baltimore) 1950; 29:299.

7. Ala, A, Stanca, CM, Bu-Ghanim, M, et al. Increased prevalence of primary biliary cirrhosis near Superfund toxic waste sites. Hepatology 2006; 43:525.

8. Alabraba, E, Nightingale, P, Gunson, B, et al. A re-evaluation of the risk factors for the recurrence of primary sclerosing cholangitis in liver allografts. Liver Transpl 2009; 15:330.

9. Alallam A, Barth D, Heathcote EJ. Role of plasmapheresis in the treatment of severe pruritus in pregnant patients with primary biliary cirrhosis: case reports. Can J Gastroenterol 2008; 22:505.

10. Al-Chalabi T, Portmann BC, BernalW, McFarlane IG, Heneghan MA.Autoimmune hepatitis overlap syndromes: an evaluation of treatmentresponse, long-term outcome and survival. Aliment Pharmacol Ther2008;28:209-220.

11. Alvarez F, Berg PA, Bianchi FB, Bianchi L, Burroughs AK,Cancado EL, et al. International Autoimmune Hepatitis GroupReport: review of criteria for diagnosis of autoimmune hepatitis.J Hepatol 1999;31(5):929–938

12. Amano, K, Leung, PS, Xu, Q, et al. Xenobiotic-induced loss of tolerance in rabbits to the mitochondrial autoantigen of primary biliary cirrhosis is reversible. J Immunol 2004; 172:6444.

13. Ang TL, Fock KM, Ng TM, Teo EK, Chua TS, Tan JY.Clinical profile of primary sclerosing cholangitis in Singapore. J Gastroenterol Hepatol 2002;17:908-913.

14. Angulo P, Jorgensen RA, Kowdley KV, Lindor KD. Silymarin in the treatment of patients with primary sclerosing cholangitis: an open-label pilot study. Dig Dis Sci 2007. Available at: http://www.springer.com. DOI:10.1007/570620-007-0052-6.

15. Angulo P, Lindor KD. Primary sclerosing cholangitis. Hepatology 1999; 30: 325-332

16. Angulo P, Pearce DH, JohnsonCD,Henry JJ, LaRussoNF, Petersen BT,et al. Magnetic resonance cholangiography in patients with biliary disease: its role in primary sclerosing cholangitis. J Hepatol 2000;33:520-527.

17. Angulo P, Therneau TM, Jorgensen A, DeSotel CK, Egan KS, DicksonER, et al. Bone disease in patients with primary sclerosing cholangitis:prevalence, severity and prediction of progression. J Hepatol 1998;29:729-735.

18. Asada M, Nishio A, Uchida K et al (2006) Identification of anovel autoantibody against pancreatic secretory trypsin inhibitorin patients with autoimmune pancreatitis. Pancreas 33:20–6

19. Bambha, K, Kim, WR, Talwalkar, J, et al. Incidence, clinical spectrum, and outcomes of primary sclerosing cholangitis in a United States community. Gastroenterology 2003; 125:1364.

20. Bang SJ, Kim MH, Kim do H *et al.* Is pancreatic core biopsy sufficient to diagnose autoimmune chronic pancreatitis? *Pancreas* 36 (1), 84-89 (2008).

21. BangarulingamSY, Gossard AA, Petersen BT,Ott BJ, Lindor KD. Complications of endoscopic retrograde cholangiopancreatography in primarysclerosing cholangitis. Am J Gastroenterol 2009;104:855-860.

22. Batta, AK, Salen, G, Mirchandani, R, et al. Effect of long-term treatment with ursodiol on clinical and biochemical features and biliary bile acid metabolism in patients with primary biliary cirrhosis. Am J Gastroenterol 1993; 88:691.

23. Battezzati, PM, Zuin, M, Crosignani, A, et al. Ten-year combination treatment with colchicine and ursodeoxycholic acid for primary biliary cirrhosis: a double-blind, placebo-controlled trial on symptomatic patients. Aliment Pharmacol Ther 2001; 15:1427.

24. Bayerdörffer, E, Mannes, GA, Richter, WO, et al. Increased serum deoxycholic acid levels in men with colorectal adenomas. Gastroenterology 1993; 104:145.

25. Ben-Ari Z, Broida E, Monselise Y, Kazatsker A, Baruch J, Pappo O, et al. Syncytial giant-cell hepatitis due to autoimmune hepatitis type II (LKM1?) presenting as subfulminant hepatitis. Am J Gastroenterol 2000;95(3):799–801

26. Bendetti A, Alvaro D, Bassoti C, Gigliozzi A, FerrettiG, La Rosa T, et al. Cytotoxicity of bile salts against biliary epithelium:a study in isolated bile ductule fragments and isolated perfused rat liver. Hepatology . 1997;26:9-21.(pubmed:9214446)

27. Bergasa NV. Treatment of the Pruritus of Cholestasis. Curr Treat Options Gastroenterol 2004; 7:501.

28. Bergquist A, Glaumann H, Lindberg B, Broome U. Primary sclerosing cholangitis can present with acute liver failure: Report of two cases. J Hepatol. 2006;44:1005-1008

29. Bergquist A, Said K, Broome U. Changes over a 20-year period in the clinical presentation of primary sclerosing cholangitis in Sweden. Scand J Gastroenterol 2007; 42: 88-93

30. Bergquist, A, Ekbom, A, Olsson, R, et al. Hepatic and extrahepatic malignancies in primary sclerosing cholangitis. J Hepatol 2002; 36:321.

31. Bergquist, A, Lindberg, G, Saarinen, S, Broomé, U. Increased prevalence of primary sclerosing cholangitis among first-degree relatives. J Hepatol 2005; 42:252.

32. Bergquist, A, Montgomery, SM, Bahmanyar, S, et al. Increased risk of primary sclerosing cholangitis and ulcerative colitis in first-degree relatives of patients with primary sclerosing cholangitis. Clin Gastroenterol Hepatol 2008; 6:939.

33. Berstad AE, Aabakken L, Smith HJ, Aasen S, Boberg KM, Schrumpf E.Diagnostic accuracy of magnetic resonance and endoscopic retrogradecholangiography in primary sclerosing cholangitis. Clin GastroenterolHepatol 2006;4:514-520.

34. Beuers U, Rust C. Overlap syndromes. Semin Liver Dis 2005;25:311-320.

35. Beuers U, Spengler U, KruisW, Aydemir U,Wiebecke B, HeldweinW,et al. Ursodeoxycholic acid for treatment of primary sclerosing cholangitis: a placebo-controlled trial. HEPATOLOGY 1992;16:707-714.

36. Beuers U. Drug insight: Mechanisms and sites of actionof ursodeoxycholic acid in cholestasis. Nat Clin PractGastroenterol Hepatol 2006;3:318-328.

37. Bjo ¨rnsson E, Boberg KM, Cullen S, Fleming K, ClausenOP, Fausa O, et al. Patients with small duct primarysclerosing cholangitis have a favourable long term prognosis. Gut 2002;51:731-735.

38. Bjo ¨rnsson E, Lindqvist-Ottosson J, Asztely M, Olsson R.Dominant strictures in patients with primary sclerosingcholangitis. Am J Gastroenterol 2004;99:502-508.

39. Björnsson, E, Olsson, R, Bergquist, A, et al. The natural history of small-duct primary sclerosing cholangitis. Gastroenterology 2008; 134:975.

40. Björnsson, E, Talwalkar, J, Treeprasertsuk, S, et al. Drug-induced autoimmune hepatitis: clinical characteristics and prognosis. Hepatology 2010; 51:2040.

41. Bloom S, Fleming K, Chapman R. Adhesion molecule expression in primary sclerosing cholangitis and primary biliary cirrhosis. Gut 1995; 36: 604-609

42. Boberg K M, E. Aadland, J. Jahnsen, N. Raknerud, M. Stiris,and H. Bell, “Incidence and prevalence of primary biliarycirrhosis, primary sclerosing cholangitis, and autoimmunehepatitis in a norwegian population,” Scandinavian Journal ofGastroenterology, vol. 33, no. 1, pp. 99–103, 1998

43. Boberg KM. Prevalence and epidemiology of autoimmune hepatitis.Clin Liver Dis 2002; 6: 635-647.**

44. Bogdanos DP, Choudhuri K, Vergani D. Molecular mimicry and autoimmune liver disease: virtuous intentions, malign consequences. Liver 2001; 21: 225-232

45. Bogdanos, DP, Baum, H, Grasso, A, et al. Microbial mimics are major targets of cross reactivity with human pyruvate dehydrogenase in primary biliary cirrhosis. J Hepatol 2004; 40:31.

46. Boulougouris G, McLeod JD, Patel YI, Ellwood CN, Walker LS, Sansom DM. Positive and negative regulation of human Tcell activation mediated by the CTLA-4/CD28 ligand CD80.J Immunol 1998;161(8):3919–3924

47. Brandsaeter B, Friman S, Broome U, IsoniemiH,OlaussonM, BackmanL, et al. Outcome following liver transplantation for primary sclerosingcholangitis in the Nordic countries. Scand J Gastroenterol 2003;38:1176-1183

48. Brandt, DJ, MacCarty, RL, Charboneau, JW, et al. Gallbladder disease in patients with primary sclerosing cholangitis. AJR Am J Roentgenol 1988; 150:571.

49. Bridoux-Henno, L, Maggiore, G, Johanet, C, et al. Features and outcome of autoimmune hepatitis type 2 presenting with isolated positivity for anti-liver cytosol antibody. Clin Gastroenterol Hepatol 2004; 2:825.

50. Brooke BN, Dykes PW, Walker FC. A study of l iver disorder in ulcerative colitis. Postgrad Med J 1961; 37: 245-251

51. Broome U, Olsson R, Loof L, Bodemar G, Hultcrantz R, Danielsson A,et al. Natural history and prognostic factors in 305 Swedish patients withprimary sclerosing cholangitis. Gut 1996;38:610-615.

52. Bruggraber, SF, Leung, PS, Amano, K, et al. Autoreactivity to lipoate and a conjugated form of lipoate in primary biliary cirrhosis. Gastroenterology 2003; 125:1705.

53. Cameron, JL, Pitt, HA, Zinner, MJ, et al. Resection of hepatic duct bifurcation and transhepatic stenting for sclerosing cholangitis. An Surg 1988; 207:614.

54. Campbell MS, Lichtenstein GR, Rhim AD, Pazianas M, Faust T. Severity of liver disease does not predict osteopenia or low bonemineral densityin primary sclerosing cholangitis. Liver Int 2005;25:311-316.

55. Candia L., J.Marquez, and L. R. Espinoza, “Autoimmune hepatitis and pregnancy: a rheumatologist’s dilemma,” Seminarsin Arthritis and Rheumatism, vol. 35, no. 1, pp. 49–56, 2005.

56. Cangemi, JR, Wiesner, RH, Beaver, SJ, et al. Effect of proctocolectomy for chronic ulcerative colitis on the natural history of primary sclerosing cholangitis. Gastroenterology 1989; 96:790.

57. Caramella, C, Avouac, J, Sogni, P, et al. Association between rheumatoid arthritis and primary biliary cirrhosis. Joint Bone Spine 2007; 74:279.

58. Carpenter HA, Czaja AJ. The role of histologic evaluation in the diagnosis and management of autoimmune hepatitis and its variants. ClinLiver Dis 2002;6:685-705.

59. Cavazza, A, Caballería, L, Floreani, A, et al. Incidence, risk factors, and survival of hepatocellular carcinoma in primary biliary cirrhosis: comparative analysis from two centers. Hepatology 2009; 50:1162.

60. Chalasani N, Baluyut A, Ismail A, Zaman A, Sood G, Ghalib R, et al.Cholangiocarcinoma in patients with primary sclerosing cholangitis: amulticenter case-control study. HEPATOLOGY 2000;31:7-11.

61. Chang WI, Kim BJ, Lee JK *et al.* The clinical and radiological characteristics of focal mass-forming autoimmune pancreatitis: comparison with chronic pancreatitis and pancreatic cancer. *Pancreas* DOI: 10.1097/MPA. 0b013e31818d92c0 (2008) (Epub ahead of print).

62. Chapman RW, Arborgh BA, Rhodes JM, Summerfield JA, Dick R,Scheuer PJ, et al. Primary sclerosing cholangitis: a review of its clinicalfeatures, cholangiography, and hepatic histology. Gut 1980;21:870-877.

63. Chapman RW, Kelly PM, Heryet A, Jewell DP, Fleming KA.Expression of HLA-DR antigens on bile duct epithelium in primary sclerosing cholangitis. Gut 1988; 29: 422-427

64. Chapman, R, Fevery, J, Kalloo, A, et al. Diagnosis and management of primary sclerosing cholangitis. Hepatology 2010; 51:660.

65. Charatcharoenwitthaya P, Lindor KD. Primary sclerosing cholangitis: diagnosis and management. Curr Gastroenterol Rep 2006; 8: 75-82

66. Charatcharoenwitthaya, P, Pimentel, S, Talwalkar, JA, et al. Long-term survival and impact of ursodeoxycholic acid treatment for recurrent primary biliary cirrhosis after liver transplantation. Liver Transpl 2007; 13:1236.

67. Chari ST, Longnecker DS, Kloppel G. The diagnosis of autoimmune pancreatitis: a Western perspective. Pancreas 2009; 38:846–848. This study introduced the concept of type 1 and type 2 AIP.

68. Chari ST, Takahashi N, Levy MJ, et al. A diagnostic strategy to distinguish autoimmune pancreatitis from pancreatic cancer. Clin Gastroenterol Hepatol2009; 7:1097–1103. This study outlines an algorithm to differentiate AIP from pancreatic cancer basedon the United States experience of AIP

69. Chazouillères, O, Wendum, D, Serfaty, L, et al. Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome: clinical features and response to therapy. Hepatology 1998; 28:296

70. Chen M, Shirai M, Liu Z, Arichi T, Takahashi H, Nishioka M. Efficient class II major histocompatibility complex presentation of endogenously synthesized hepatitis C virus core protein byEpstein-Barr virus-transformed B-lymphoblastoid cell lines to CD4(+) T cells. J Virol 1998; 72: 8301-8308

71. Christensen, E, Altman, DG, Neuberger, J, et al. Updating prognosis in primary biliary cirrhosis using a time-dependent Cox regression model. PBC1 and PBC2 trial groups. Gastroenterology 1993; 105:1865.

72. Chung H., T. Watanabe, M. Kudo, O. Maenishi, Y. Wakatsuki,and T. Chiba, “Identification and characterization of IgG4-associated autoimmune hepatitis,” Liver International, vol. 30,no. 2, pp. 222–231, 2010.

73. Combes B, Emerson SS, Flye NL. The primary biliary cirrhosis (PBC) ursodiol (UDCA) plus methotrexate (MTX) or its placebo study (PUMPS) - a multicenter randomized trial. Hepatology 2003;38:210A-210A. abstract.

74. Combes, B, Emerson, SS, Flye, NL, et al. Methotrexate (MTX) plus ursodeoxycholic acid (UDCA) in the treatment of primary biliary cirrhosis. Hepatology 2005; 42:1184.

75. Combes, B, Markin, RS, Wheeler, DE, et al. The effect of ursodeoxycholic acid on the florid duct lesion of primary biliary cirrhosis. Hepatology 1999; 30:602.

76. Cooper GS, Bynum ML, Somers EC: Recent insights in the epidemiology of autoimmune diseases: Improved prevalence estimates and understanding of clustering of diseases. J Autoimmun 2009, 33:197-207.

77. Corpechot C, Carrat F, Bahr A, Chretien Y, Poupon RE, Poupon R. The effect of ursodeoxycholic acid therapy on the natural course of primary biliary cirrhosis. Gastroentrology**128**: 297-303, 2005.

78. Corpechot C, Abenavoli L, Rabahi N, et al. Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis. Hepatology **48**: 871-877, 2008.

79. Cotler SJ, Jakate S, Jensen DM. Resolution of cirrhosis in autoimmune hepatitis with corticosteroid therapy.*J. Clin. Gastroenterol*. 2001; 32: 428-30.

80. Cruickshank SM, Southgate J, Selby PJ, Trejdosiewicz LK. Inhibition of T cell activation by normal human biliary epithelial cells. J Hepatol 1999; 31: 1026-1033

81. Cullen SN, Chapman RW. Review article: current management of primary sclerosing cholangitis. Aliment Pharmacol Ther 2005;21:933-948.

82. Cullen SN, Chapman RW. The medical management of primary sclerosing cholangitis. Semin Liver Dis 2006;26:52-61.

83. Czaja A.J., “Features and consequences of untreated type 1autoimmune hepatitis,” Liver International,vol.29,no.6, pp.816–823, 2009.

84. Czaja A.J., “Variant forms of autoimmune hepatitis,” CurrentGastroenterology Reports, vol. 1, no. 1, pp. 63–70, 1999.

85. Czaja AJ, Carpenter HA, Santrach PJ, Moore SB. Genetic predispositions for the immunological features of chronic active hepatitis. Hepatology 1993; 18:816.

86. Czaja AJ, Carpenter HA, Santrach PJ, Moore SB. Significance ofHLA DR4 in type 1 autoimmune hepatitis. Gastroenterology 1993;105:1502-1507.

87. Czaja AJ, Carpenter HA. Decreased fibrosis during corticosteroid therapy of autoimmune hepatitis. Hepatol. 2004; 40:646-52.

88. Czaja AJ, Davis GL, Ludwig J, et al. Autoimmune features as determinants of prognosis in steroid-treated chronic active hepatitis of uncertain etiology. Gastroenterology 1983; 85:713.

89. Czaja AJ, Shums Z, Norman GL. Nonstandard antibodies as prognos-tic markers in autoimmune hepatitis. Autoimmunity 2004;37:195-201.

90. Czaja AJ, Wolf AM, Baggenstoss AH. Laboratory assessment of severe chronic active liver disease during and after corticosteroid therapy: correlation of serum transaminase and gamma globulin levels with histologic features. Gastroenterology 1981; 80:687.

91. Czaja AJ. Autoimmune hepatitis. Part B: diagnosis. Expert Rev Gas-troenterol Hepatol 2007;1:129-143.

92. Czaja AJ. Behavior and significance of autoantibodies in type 1 auto-immune hepatitis. J Hepatol 1999;30:394-401

93. Czaja AJ. Performance parameters of the diagnostic scoring systems for autoimmune hepatitis. HEPATOLOGY 2008;48:1540-1548.

94. Czaja AJ. Safety issues in the management of autoimmune hepatitis.Expert Opin Drug Safety 2008;7:319-333.

95. Czaja AJ. Special clinical challenges in autoimmune hepatitis:the elderly, males, pregnancy, mild disease, fulminant onset, andnonwhite patients. Semin Liver Dis 2009;29(3):315–330

96. Czaja, AJ, Carpenter, HA, Manns, MP. Antibodies to soluble liver antigen, P450IID6, and mitochondrial complexes in chronic hepatitis. Gastroenterology 1993; 105:1522

97. Czaja, AJ. The variant forms of autoimmune hepatitis. Ann Intern Med 1996; 125:588.

98. Czaja. The role of autoantibodies as diagnostic markers of autoim-mune hepatitis. Expert Rev Clin Immunol 2006;2:33-48.

99. D'Souza R., P. Sinnott, M. J. Glynn, C. A. Sabin, and G.R. Foster, "An unusual form of autoimmune hepatitis inyoung Somalian men," Liver International,vol.25,no.2,pp.325–330, 2005.

100. DATTA DV, SHERLOCK S. Treatment of pruritus of obstructive jaundice with cholestyramine. Br Med J 1963; 1:216.

101. Davidson, A, Diamond, B. Autoimmune diseases. N Engl J Med 2001; 345:340.

102. Davies, YK, Cox, KM, Abdullah, BA, et al. Long-term treatment of primary sclerosing cholangitis in children with oral vancomycin: an immunomodulating antibiotic. J Pediatr Gastroenterol Nutr 2008; 47:61.

103. Degott, C, Zafrani, ES, Callard, P, et al. Histopathological study of primary biliary cirrhosis and the effect of ursodeoxycholic acid treatment on histology progression. Hepatology 1999; 29:1007.

104. Demetris AJ, Adeyi O, Bellamy CO, Clouston A, Charlotte F, CzajaA, et al. Liver biopsy interpretation for causes of late liver allograftdysfunction. HEPATOLOGY 2006;44:489-501

105. Dickson, E, Fleming, C, Ludwig, J. Primary biliary cirrhosis. In: Progress in Liver Diseases, Vol. 6, Popper, H, Schaffner, F (Eds), Grune and Stratton, New York 1978. p.487.

106. Dickson, ER, Grambsch, PM, Fleming, TR, et al. Prognosis in primary biliary cirrhosis: model for decision making. Hepatology 1989; 10:1.

107. DoddGD3rd, Baron RL,Oliver JH3rd, FederleMP. End-stage primarysclerosing cholangitis: CT findings of hepatic morphology in 36 patients.Radiology 1999;211:357-362.

108. Doherty, DG, Donaldson, PT, Underhill, JA, et al. Allelic sequence variation in the HLA class II genes and proteins in patients with autoimmune hepatitis. Hepatology 1994; 19:609.

109. Donaldson, PT, Albertini, et al. Immunogenetic studies of autoimmune hepatitis and primary sclerosing cholangitis. In: Elsevier Science, Krawitt, EL, Wiesner, RH, Nishioka, M (Eds), Amsterdam 1998.

110. Duclos-Vallee JC, Sebagh M, Rifai K, Johanet C, Ballot E, GuettierC, et al. A 10 year follow up study of patients transplanted for auto-immune hepatitis: histological recurrence precedes clinical and bio-chemical recurrence. Gut 2003;52:893-897

111. Eckhauser, FE, Colleti, LM, Knol, JA. The changing role of surgery for sclerosing cholangitis. Dig Dis 1996; 14:180.

112. Ectores N, Maillet B, Aerts R, et al. Non-alcoholic duct destructive chronic pancreatitis. Gut 1997;41:263-268.

113. El younis cm, min ad, fiel mi, et al. autoimmune hepatitis in a patient with sickle cell disease. am j gastroenterol 1996; 91:1016.

114. Elion GB. The George Hitchings and Gertrude Elion Lecture. The pharmacology of azathioprine. *Ann. N. Y. Acad. Sci.* 1993; 685: 400-07

115. Elta, GH, Sepersky, RA, Goldberg, MJ, et al. Increased incidence of hypothyroidism in primary biliary cirrhosis. Dig Dis Sci 1983; 28:971.

116. Endo T, Takizawa S, Tanaka S, Takahashi M, Fujii H, KamisawaT, Kobayashi T (2009) Amylase alpha-2A autoantibodies: novelmarker of autoimmune pancreatitis and fulminant type 1 diabetes.Diabetes 58:732–7

117. European Liver Transplant Registry, http://www.eltr.org/.

118. Farges, O, Malassagne, B, Sebagh, M, Bismuth, H. Primary sclerosing cholangitis: liver transplantation or biliary surgery. Surgery 1995; 117:146.

119. Färkkilä, M, Karvonen, AL, Nurmi, H, et al. Metronidazole and ursodeoxycholic acid for primary sclerosing cholangitis: a randomized placebo-controlled trial. Hepatology 2004; 40:1379.

120. Farkkila, MA, Karkkainen, P, Karvonen, AL, et al. Combination of ursodeoxycholic acid (UDCA) and metronidazole (MTZ) in PSC: Reduction of inflammation in liver correlates with the decrease of the New Mayo Risk Score (abstract). Gastroenterology 2003; 124:A707.

121. Feld JJ, Dinh H, Arenovich T, Marcus VA, Wanless IR, HeathcoteEJ. Autoimmune hepatitis: effect of symptoms and cirrhosis on natural history and outcome. HEPATOLOGY 2005;42:53-62.

122. Fernandes NF, Redeker AG, Vierling JM, et al. Cyclosporine therapy in patients with steroid resistant autoimmune hepatitis. Am J Gastroenterol 1999; 94:241.

123. Fickert P, Fuchsbichler A, Wagner M, Zollner G, Kaser A, Tilg , Krause R, Lammert F, Langner C, Zatloukal K, Marschall HU, Denk H, Trauner M. Regurgitation of bile acids fromleaky bile ducts causes sclerosing cholangitis in Mdr2 (Abcb4) knockout mice. Gastroenterology 2004; 127: 261-274

124. Fickert, P, Wagner, M, Marschall, HU, et al. 24-norUrsodeoxycholic acid is superior to ursodeoxycholic acid in the treatment of sclerosing cholangitis in Mdr2 (Abcb4) knockout mice. Gastroenterology 2006; 130:465.

125. Finkelberg, DL, Sahani, D, Deshpande, V, Brugge, WR. Autoimmune pancreatitis. N Engl J Med 2006; 355:2670.

126. Fleming, CR, Dickson, ER, Hollenhorst, RW, et al. Pigmented corneal rings in a patient with primary biliary cirrhosis. Gastroenterology 1975; 69:220.

127. Forton DM, Patel N, Prince M, et al. Fatigue and primary biliary cirrhosis: association of globus pallidus magnetisation transfer ratio measurements with fatigue severity and blood manganese levels. Gut 2004;53:587-592.

128. Frenzel, C, Herkel, J, Lüth, S, et al. Evaluation of F-actin ELISA for the diagnosis of autoimmune hepatitis. Am J Gastroenterol 2006; 101:2731.

129. Fritscher-Ravens A, Broering DC, Knoefel WT, et al. EUS-guided fine-needle aspiration of suspected hilar cholangiocarcinoma in potentially operable patients with negative brush cytology. Am J Gastroenterol 2004; 99:45.

130. Frulloni L, Lunardi C, Simone R et al (2009) Identification of anovel antibody associated with autoimmune pancreatitis. N Engl JMed 361:2135–42

131. Frulloni L, Scattolini C, Falconi M, et al. Autoimmune pancreatitis: differences between the focal and diffuse forms in 87 patients. Am J Gastroenterol 2009;104:2288-2294.

132. Frulloni, L, Lunardi, C, Simone, R, et al. Identification of a novel antibody associated with autoimmune pancreatitis. N Engl J Med 2009; 361:2135.

133. Fusconi M, Vannini A, Dall'Aglio AC, Pappas G, Cassani F,Ballardini G, et al. Anti-cyclic citrullinated peptide antibodies intype 1 autoimmune hepatitis. Aliment Pharmacol Ther 2005;22(10):951–955

134. Garber, T, Farrell, TJ. Autoimmune Pancreatitis: Time for a single Nomenclature (abstract). Gastroenterology 2004; 126(Suppl 2):255.

135. Ghazale A, Chari ST, Smyrk TC *et al.* Value of serum IgG4 in the diagnosis of autoimmune pancreatitis and in distinguishing it from pancreatic cancer. *Am. J. Gastroenterol.* 102(8),1646-1653 (2007).

136. Ghazale A, Chari ST, Zhang L, et al. Immunoglobulin G4-associated cholangitis: clinical profile and response to therapy. Gastroenterology 2008;134:706–715.

137. Ghent CN, Bloomer JR, Klatskin G. Elevations in skin tissue levels of bile acids in human cholestasis: relation to serum levels and topruritus. Gastroenterology 1977; 73:1125.

138. Ghent CN, Carruthers SG. Treatment of pruritus in primary biliary cirrhosis with rifampin. Results of a double-blind, crossover, randomized trial. Gastroenterology 1988; 94:488.

139. Ghent CN. Pruritus of cholestasis is related to effects of bile salts on the liver, not the skin. Am J Gastroenterol 1987; 82:117.

140. GluckM, Cantone NR, Brandabur JJ, Patterson DJ, Bredfeldt JE, Kozarek RA. A twenty-year experience with endoscopic therapy for symptomatic primary sclerosing cholangitis. J Clin Gastroenterol 2008;42:1032-1039

141. Goelz, SE, Vogelstein, B, Hamilton, SR, Feinberg, AP. Hypomethylation of DNA from benign and malignant human colon neoplasms. Science 1985; 228:187.

142. Gow PJ, Fleming KA, Chapman RW. Primary sclerosing cholangitis associated with rheumatoid arthritis and HLA DR4: is the association a marker of patients with progressive liver disease? J Hepatol 2001; 34: 631-635

143. Gregorio GV, McFarlane B, Bracken P, Vergani D, Mieli-Vergani G.Organ and non-organ specific autoantibody titres and IgG levels asmarkers of disease activity: a longitudinal study in childhood autoim-mune liver disease. Autoimmunity 2002;35:515-519

144. Gregorio GV, Portmann B, Reid F, et al. Autoimmune hepatitis in childhood: a 20-year experience. Hepatology 1997; 25:541.

145. Guanabens N, Pares A, Ros I, et al. Alendronate is more effective than etidronate for increasing bone mass in osteopenic patients with primary biliary cirrhosis. Am J Gastroenterol 2003;98:2268-2274

146. Guañabens, N, Parés, A, Mariñoso, L, et al. Factors influencing the development of metabolic bone disease in primary biliary cirrhosis. Am J Gastroenterol 1990; 85:1356.

147. Guañabens, N, Parés, A, Ros, I, et al. Severity of cholestasis and advanced histological stage but not menopausal status are the major risk factors for osteoporosis in primary biliary cirrhosis. J Hepatol 2005; 42:573.

148. Guarneri F, Guarneri C, Benvenga S (3) Helicobacter pylori and autoimmune pancreatitis: role of carbonic anhydrase via molecularmimicry? J Cell Mol Med 9(3):741–4

149. Hamano H, Kawa S, Horiuchi A *et al*. High serum IgG4 concentrations in patients with sclerosing pancreatitis. *N. Engl. J. Med.* 344(10),732-738 (2001).

150. Harrison, RF, Davies, MH, Neuberger, JM, Hubscher, SG. Fibrous and obliterative cholangitis in liver allografts: evidence of recurrent primary sclerosing cholangitis? Hepatology 1994; 20:356.

151. Hatzis, GS, Fragoulis, GE, Karatzaferis, A, et al. Prevalence and longterm course of primary biliary cirrhosis in primary Sjögren's syndrome. J Rheumatol 2008; 35:2012.

152. Hay, JE. Bone disease in cholestatic liver disease. Gastroenterology 1995; 108:276.

153. Helzberg JH, Petersen JM, Boyer JL. Improved survival with primary sclerosing cholangitis. A review of clinicopathologic features and comparison of symptomatic and asymptomatic patients. Gastroenterology. 1987;92:1869-1875

154. Heneghan MA, Norris SM, O'Grady JG, Harrison PM, Mcfarlane IG. Management and outcome of pregnancy in autoimmunehepatitis. Gut 2001;48(1):97–102

155. Hennes EM, Oo YH, Schramm C, et al. Mycophenolate mofetil as second line therapy in autoimmune hepatitis? Am J Gastroenterol 2008; 103:3063.

156. Hennes EM, Zeniya M, Czaja AJ, Pares A, Dalekos GN, Krawitt EL,et al. Simplified criteria for the diagnosis of autoimmune hepatitis.HEPATOLOGY 2008;48:169-176.

157. Hill, MJ, Melville, DM, Lennard-Jones, JE, et al. Faecal bile acids, dysplasia, and carcinoma in ulcerative colitis. Lancet 1987; 2:185.

158. Hillaire, S, Boucher, E, Calmus, Y, et al. Effects of bile acids and cholestasis on major histocompatibility complex class I in human and rat hepatocytes. Gastroenterology 1994; 107:781.

159. Hindorf U, Jahed K, Bergquist A, et al. Characterisation and utility of thiopurine methyltransferase and thiopurine metabolite measurements in autoimmune hepatitis. J Hepatol 2010; 52:106.

160. Hirano K, Tada M, Isayama H, et al. Long-term prognosis of autoimmune pancreatitis with and without corticosteroid treatment. Gut. 2007;56:1719Y1724.

161. Hirschfield GM, Al-Harthi N, Heathcote EJ: Review Current. Status of Therapy in Autoimmune Liver Disease. Ther Adv troenterol 2009, 2:11-28.

162. Hirschfield, GM, Liu, X, Han, Y, et al. Variants at IRF5-TNPO3, 17q12-21 and MMEL1 are associated with primary biliary cirrhosis. Nat Genet 2010; 42:655.

163. Hirschfield, GM, Liu, X, Xu, C, et al. Primary biliary cirrhosis associated with HLA, IL12A, and IL12RB2 variants. N Engl J Med 2009; 360:2544.

164. Hodgson, SF, Dickson, ER, Wahner, HW, et al. Bone loss and reduced osteoblast function in primary biliary cirrhosis. Ann Intern Med 1985; 103:855.

165. Hollingsworth, KG, Newton, JL, Taylor, R, et al. Pilot study of peripheral muscle function in primary biliary cirrhosis: potential implications for fatigue pathogenesis. Clin Gastroenterol Hepatol 2008; 6:1041.

166. Homberg JC, Abuaf N, Bernard O, Islam S, Alvarez F, Khalil SH,et al. Chronic active hepatitis associated with anti liver/kidney microsome type 1: a second type of ‘‘autoimmune’’ hepatitis. HEPATOLOGY1987;7:1333-1339.

167. Hubscher SG. Recurrent autoimmune hepatitis after liver transplantation: diagnostic criteria, risk factors, and outcome. Liver Transpl2001;7:285-291.

168. Huppertz, J, Coriat, R, Leblanc, S, et al. Application of Anaes guidelines for colonoscopy in France: A practical survey. Gastroenterol Clin Biol 2010.

169. Hurlburt KJ, McMahon BJ, Deubner H, Hsu-TrawinskiB, Williams JL, Kowdley KV. Prevalence of autoimmuneliver disease in Alaska natives. Am J Gastroenterol 2002;97:2402-2407.

170. Ichai P, Duclos-Vallee JC, Guettier C, Hamida SB, Antonini T, Delvart V, et al. Usefulness of corticosteroids for the treatment of severeand fulminant forms of autoimmune hepatitis. Liver Transpl 2007;13:996-1003

171. Invernizzi P, Selmi C, Ranftler C, Podda M, Wesierska-Gadek J: Antinuclear antibodies in primary biliary cirrhosis. Semin Liver Dis 2005, 25:298-310.

172. Invernizzi, P, Crosignani, A, Battezzati, PM, et al. Comparison of the clinical features and clinical course of antimitochondrial antibody-positive and -negative primary biliary cirrhosis. Hepatology 1997; 25:1090.

173. Ishikawa M, Okada J, Shibuya A, Kondo H. CRST syndrome (calcinosis cutis, Raynaud's phenomenon, sclerodactyly, and telangiectasia) associated with autoimmune hepatitis. Intern Med 1995; 34:6.

174. James, SP, Hoofnagle, JH, Strober, W, Jones, EA. NIH conference: Primary biliary cirrhosis: a model auoimmune disease. Ann Intern Med 1983; 99:500.

175. Johnson PJ, McFarlane IG, Williams R. Azathioprisne for long-term maintenance of remission in autoimmune hepatitis. N Engl J Med 1995;333:958-963.

176. Johnson, PJ, McFarlane, IG. Meeting report: International Autoimmune Hepatitis Group. Hepatology 1993; 18:998.

177. Jones EA, Neuberger J, Bergasa NV. Opiate antagonist therapy for the pruritus of cholestasis: the avoidance of opioid withdrawal-like reactions. QJM 2002; 95:547.

178. Jones, DE, Metcalf, JV, Collier, JD, et al. Hepatocellular carcinoma in primary biliary cirrhosis and its impact on outcomes. Hepatology 1997; 26:1138.

179. Jones, DE, Newton, JL. An open study of modafinil for the treatment of daytime somnolence and fatigue in primary biliary cirrhosis. Aliment Pharmacol Ther 2007; 25:471.

180. Jones, EA, Bergasa, NV. Why do cholestatic patients itch? Gut 1996; 38:644.

181. Jones, EA. Rationale for trials of long-term mycophenolate mofetil therapy for primary biliary cirrhosis. Hepatology 2002; 35:258.

182. Jorgensen, RA, Lindor, KD, Sartin, JS, et al. Serum lipid and fat-soluble vitamin levels in primary sclerosing cholangitis. J Clin Gastroenterol 1995; 20:215.

183. Juran, BD, Atkinson, EJ, Schlicht, EM, et al. Primary biliary cirrhosis is associated with a genetic variant in the 3' flanking region of the CTLA4 gene. Gastroenterology 2008; 135:1200.

184. Kajiwara M, Gotohda N, Konishi M, et al. Incidence of the focal type ofautoimmune pancreatitis in chronic pancreatitis suspected to be pancreaticcarcinoma: experience of a single tertiary cancer center. Scand J Gastroenterol 2008; 43:110–116.

185. Kamisawa T, Egawa N, Tsuruta K, Okamoto A, Funata N. Primarysclerosing cholangitis may be overestimated in Japan. J Gastroenterol2005;40:318-319.

186. Kamisawa T, Okamoto A. Autoimmune pancreatitis: proposal of IgG4-related sclerosing disease. J Gastroenterol 2006; 41:613–625.

187. Kamisawa T, Shimosegawa T, Okazaki K, et al. Standard steroid treatment forautoimmune pancreatitis. Gut 2009; 58:1504–1507. A large multicenter study which provides the strongest rationale and evidence forusing corticosteroids in the treatment of AIP

188. Kamisawa T, Takuma K, Anjiki H, et al. Differentiation of autoimmune pancreatitis from pancreatic cancer by diffusion-weighted MRI. Am J Gastroenterol 2010 Mar 9{Epub ahead of print}.

189. Kamisawa T, Yoshiike M, Egawa N, Nakajima H, Tsuruta K, Okamoto A. Treating patients with autoimmune pancreatitis: results from a long-term follow-up study. Pancreatology 2005;5:234-238.

190. Kamisawa, T, Egawa, N, Nakajima, H, et al. Clinical difficulties in the differentiation of autoimmune pancreatitis and pancreatic carcinoma. Am J Gastroenterol 2003; 98:2694.

191. Kamisawa, T, Egawa, N, Nakajima, H. Autoimmune pancreatitis is a systemic autoimmune disease. Am J Gastroenterol 2003; 98:2811.

192. Kamisawa, T, Tu, Y, Egawa, N, et al. Involvement of pancreatic and bile ducts in autoimmune pancreatitis. World J Gastroenterol 2006; 12:612.

193. Kamiyama T., T. Nouchi, S. Kojima, N. Murata, T. Ikeda, andC. Sato, “Autoimmune hepatitis triggered by administrationof an herbal medicine,” American Journal of Gastroenterology,vol. 92, no. 4, pp. 703–704, 1997.

194. Kanzler S, Gerken G, Löhr H, et al. Duration of immunosuppressive therapy in autoimmune hepatitis. J Hepatol 2001; 34:354.

195. Kaplan GG, Laupland KB, Butzner D, Urbanski SJ, Lee SS. The burden of large and small duct primary sclerosing cholangitis in adults and children: a population-based analysis. Am J Gastroenterol 2007; 102: 1042-1049

196. Kaplan MM, Cheng S, Price LL, Bonis PA. A randomized controlled trial of colchicine plus ursodiol versus methotrexate plus ursodiol in primary biliary cirrhosis: ten-year results. Hepatology 2004;39:915-923.

197. Kaplan MM, Gershwin ME: Primary biliary cirrhosis. N Engl J Med 2005, 353:1261-1273.

198. Kaplan MM, Schmid C, Provenzale D, et al. A prospective trial of colchicine and methotrexate in the treatment of primary biliary cirrhosis. Gastroenterology 1999; 117:1173-1180.

199. Kaplan, AA, Halley, SE, Reardon, J, Sevigny, J. One year's experience using a rotating filter for therapeutic plasma exchange. ASAIO Trans 1989; 35:262.

200. Kaplan, MM, Bonis, PA. Modafinil for the treatment of fatigue in primary biliary cirrhosis. Ann Intern Med 2005; 143:546.

201. Kaplan, MM, Goldberg, MJ, Matloff, DS, et al. Effect of 25-hydroxyvitamin D3 on vitamin D metabolites in primary biliary cirrhosis. Gastroenterology 1981; 81:681.

202. Kaplan, MM. Novosphingobium aromaticivorans: a potential initiator of primary biliary cirrhosis. Am J Gastroenterol 2004; 99:2147.

203. Kaplan, MM. Primary biliary cirrhosis. N Engl J Med 1996; 335:1570.

204. Karlsen TH, Lie BA, Frey Froslie K, Thorsby E, BroomeU, Schrumpf E, Boberg KM. Polymorphisms in the steroid and xenobiotic receptor gene influence survival in primary sclerosing cholangitis. Gastroenterology 2006; 131: 781-787

205. Kawa S, Ota M, Yoshizawa K *et al.* HLA DRB10405-DQB10401 haplotype is associated with autoimmune pancreatitis in the Japanese population. *Gastroenterology* 122(5),1264-1269 (2002).

206. Kaya M, Petersen BT, Angulo P, Baron TH, Andrews JC,Gostout CJ, et al. Balloon dilation compared to stentingof dominant strictures in primary sclerosing Cholangitis.Am J Gastroenterol 2001;96:1059-1066.

207. Kerkar N, Choudhuri K, Ma Y, Mahmoud A, Bogdanos DP, Muratori L, Bianchi F, Williams R, Mieli-Vergani G, Vergani D. Cytochrome P4502D6(193-212): a new immunodominant epitope and target of virus/self cross-reactivity in liverkidney microsomal autoantibody type 1-positive liver disease. J Immunol 2003; 170: 1481-1489

208. Kerkar N, Dugan C, Rumbo C, Morotti RA, Gondolesi G, ShneiderBL, et al. Rapamycin successfully treats post-transplant autoimmunehepatitis. Am J Transplant 2005;5:1085-1089.

209. Kershenobich, D, Rojkind, M, Quiroga, A, Alcocer-Varela, J. Effect of colchicine on lymphocyte and monocyte function and its relation to fibroblast proliferation in primary biliary cirrhosis. Hepatology 1990; 11:205.

210. Kessler WR, Cummings OW, Eckert G, et al. Fulminant hepatic failure as the initial presentation of acute autoimmune hepatitis. Clin Gastroenterol Hepatol 2004; 2:625.

211. Khalaf H, Mourad W, El-Sheikh Y, Abdo A, Helmy A, Medhat Y, etal. Liver transplantation for autoimmune hepatitis: a single-center ex-perience. Transplant Proc 2007;39:1166-1170.

212. Kim MH, Lee TY (2007) Diagnostic criteria for autoimmunepancreatitis: a proposal of revised Kim criteria. J GastroenterolHepatol 22:A104

213. Kim, WR, Poterucha, JJ, Jorgensen, RA, et al. Does antimitochondrial antibody status affect response to treatment in patients with primary biliary cirrhosis? Outcomes of ursodeoxycholic acid therapy and liver transplantation. Hepatology 1997; 26:22.

214. Kita, H, Matsumura, S, He, XS, et al. Quantitative and functional analysis of PDC-E2-specific autoreactive cytotoxic T lymphocytes in primary biliary cirrhosis. J Clin Invest 2002; 109:1231.

215. Kita, H, Naidenko, OV, Kronenberg, M, et al. Quantitation and phenotypic analysis of natural killer T cells in primary biliary cirrhosis using a human CD1d tetramer. Gastroenterology 2002; 123:1031.

216. Klein R, Zanger UM, Berg T, Hopf U, Berg PA. Overlapping butdistinct specificities of anti-liver-kidney microsome antibodies inautoimmune hepatitis type II and hepatitis C revealed by recombinant native CYP2D6 and novel peptide epitopes. Clin Exp Immunol1999; 118: 290-297.

217. Kotlyar DS, Campbell MS, Reddy KR. Recurrence of diseases following orthotopic liver transplantation. Am J Gastroenterol 2006;101:1370-1378.

218. Koulentaki, M, Ioannidou, D, Stefanidou, M, et al. Dermatological manifestations in primary biliary cirrhosis patients: a case control study. Am J Gastroenterol 2006; 101:541.

219. Krams, SM, Surh, CD, Coppel, RL, et al. Immunization of experimental animals with dihydrolipoamide acetyltransferase, as a purified recombinant polypeptide, generates mitochondrial antibodies but not primary biliary cirrhosis. Hepatology 1989; 9:411.

220. Krawitt, EL. Autoimmune hepatitis. N Engl J Med 2006; 354:54.

221. Kremer, AE, Martens, JJ, Kulik, W, et al. Increased serum autotaxin activity in cholestatic pruritus (abstract). Hepatology 2009; 50:376A.

222. Lanspa, SJ, Chan, AT, Bell, JS, et al. Pathogenesis of steatorrhea in primary biliary cirrhosis. Hepatology 1985; 5:837.

223. Lapierre P., I. Djilali-Saiah, S. Vitozzi, and F. Alvarez, “Amurine model of type 2 autoimmune hepatitis: xenoimmunization with human antigens,” Hepatology,vol.39,no.4,pp.1066–1074, 2004.

224. Larsen FS. Treatment of patients with severe autoimmune hepatitis.Minerva Gastroenterol Dietol 2008;54:57-63.

225. LaRusso NF, Shneider BL, Black D, Gores GJ, James SP, Doo E, Hoofnagle JH. Primary sclerosing cholangitis: summary of a workshop. Hepatology 2006; 44: 746-764

226. Laurin JM, DeSotel CK, Jorgensen RA, Dickson ER, Lindor KD. The natural history of abdominal pain associated with primary biliary cirrhosis. Am J Gastroenterol 1994;89:1840-1843

227. Lazaridis KN, Talwalkar JA: Clinical epidemiology of primary biliary cirrhosis: incidence, prevalence, and impact of therapy. J Clin Gastroenterol 2007, 41:494-500.

228. Lazaridis, KN, Juran, BD, Boe, GM, et al. Increased prevalence of antimitochondrial antibodies in first-degree relatives of patients with primary biliary cirrhosis. Hepatology 2007; 46:785.

229. Lazaridis, KN, Gores, GJ, Lindor, KD. Ursodeoxycholic acid 'mechanisms of action and clinical use in hepatobiliary disorders'. J Hepatol 2001; 35:134.

230. Lecoeur, S, André, C, Beaune, PH. Tienilic acid-induced autoimmune hepatitis: anti-liver and-kidney microsomal type 2 autoantibodies recognize a three-site conformational epitope on cytochrome P4502C9. Mol Pharmacol 1996; 50:326.

231. Lee TY, KimMH, Park do H, et al. Utility of 18F-FDGPET/CT for differentiationof autoimmune pancreatitis with atypical pancreatic imaging findings frompancreatic cancer. AJR Am J Roentgenol 2009; 193:343–348.

232. Lee YM, Kaplan MM. Primary sclerosing cholangitis. N Engl J Med1995;332:924-933.

233. Lee, J, Belanger, A, Doucette, JT, et al. Transplantation trends in primary biliary cirrhosis. Clin Gastroenterol Hepatol 2007; 5:1313.

234. Lennard L, Van Loon JA, Weinshilboum RM. Pharmacogenetics ofacute azathioprine toxicity: relationship to thiopurine methyltransferase genetic polymorphism. Clin Pharmacol Ther 1989;46:149-154

235. Leung J, Dowling L, Obadan I, et al. Risk of non-melanoma skin cancer in autoimmune hepatitis. Dig Dis Sci 2010; 55:3218.

236. Levy C, Lindor KD. Primary sclerosing cholangi t is: epidemiology, natural history, and prognosis. Semin Liver Dis 2006; 26: 22-30

237. Levy MJ, Reddy RP, Wiersema MJ, et al. EUS-guided trucut biopsy in establishing autoimmune pancreatitis as the cause of obstructive jaundice.Gastrointest Endosc 2005; 61:467–472.

238. Levy, C, Lindor, KD. Management of osteoporosis, fat-soluble vitamin deficiencies, and hyperlipidemia in primary biliary cirrhosis. Clin Liver Dis 2003; 7:901.

239. Lichtman, SN, Sartor, RB, Keku, J, Schwab, JH. Hepatic inflammation in rats with experimental small intestinal bacterial overgrowth. Gastroenterology 1990; 98:414.

240. Liermann Garcia, RF, Evangelista Garcia, C, McMaster, P, Neuberger, J. Transplantation for primary biliary cirrhosis: retrospective analysis of 400 patients in a single center. Hepatology 2001; 33:22.

241. Lindkvist, B, Benito de Valle, M, Gullberg, B, Björnsson, E. Incidence and prevalence of primary sclerosing cholangitis in a defined adult population in Sweden. Hepatology 2010; 52:571.

242. Lindor KD, Wiesner RH, Katzmann JA, LaRusso NF, BeaverSJ. Lymphocyte subsets in primary sclerosing cholangitis.Dig Dis Sci 1987; 32: 720-725

243. Lindor KD. Ursodiol for primary sclerosing cholangitis. Mayo Primary Sclerosing Cholangitis-Ursodeoxycholic Acid Study Group. N Engl J Med 1997; 336:691.

244. Lindor, KD, Gershwin, ME, Poupon, R, et al. Primary biliary cirrhosis. Hepatology 2009; 50:291.

245. Liston A, Lesage S, Gray DH, Boyd RL, Goodnow CC. Genetic lesions in T-cell tolerance and thresholds for autoimmunity. Immunol Rev 2005; 204: 87-101

246. Liu, B, Zhang, FC, Zhang, ZL, et al. Interstitial lung disease and Sjögren's syndrome in primary biliary cirrhosis: a causal or casual association? Clin Rheumatol 2008; 27:1299.

247. Lleo A, Battezzati PM, Selmi C, Gershwin ME, Podda M: Is autoimmunity a matter of sex? Autoimmun Rev 2008, 7:626-630.

248. Locke GR, 3rd, Therneau, TM, Ludwig, J, et al. Time course of histological progression in primary biliary cirrhosis. Hepatology 1996; 23:52-56.

249. Löfberg, R, Broström, O, Karlén, P, et al. DNA aneuploidy in ulcerative colitis: reproducibility, topographic distribution, and relation to dysplasia. Gastroenterology 1992; 102:1149.

250. Long, RG, Scheuer, PJ, Sherlock, S. Presentation and course of asymptomatic primary biliary cirrhosis. Gastroenterology 1977; 72:1204.

251. Longhi MS, Hussain MJ, Bogdanos DP, Quaglia A, Mieli-Vergani G, Ma Y, Vergani D. Cytochrome P450IID6-specific CD8 T cell immune responses mirror disease activity in ssautoimmune hepatitis type 2. Hepatology 2007; 46: 472-484

252. Ludwig, J, Barham, SS, LaRusso, NF, et al. Morphologic features of chronic hepatitis associated with primary sclerosing cholangitis and chronic ulcerative colitis. Hepatology 1981; 1:632.

253. Luettig, B, Boeker, KH, Schoessler, W, et al. The antinuclear autoantibodies Sp100 and gp210 persist after orthotopic liver transplantation in patients with primary biliary cirrhosis. J Hepatol 1998; 28:824.

254. M. Ota, T. Seki, K. Kiyosawa et al., "A possible associationbetween basic amino acids of position 13 of DRB1 chains andautoimmune hepatitis," Immunogenetics, vol. 36, no. 1, pp.49–55, 1992.

255. Ma Y, Bogdanos DP, Hussain MJ, Underhill J, Bansal S, Longhi MS, Cheeseman P, Mieli-Vergani G, Vergani D. Polyclonal T-cell responses to cytochrome P450IID6 are associated with disease activity in autoimmune hepatitis type 2. Gastroenterology 2006; 130: 868-882.

256. Ma Y, Okamoto M, Thomas MG, Bogdanos DP, Lopes AR, Portmann B, Underhill J, Dürr R, Mieli-Vergani G, Vergani D. Antibodies to conformational epitopes of soluble liver antigen define a severe form of autoimmune liver disease. Hepatology 2002; 35: 658-664

257. MacCarty RL, LaRusso NF, May GR, Bender CE, WiesnerRH, King JE, et al. Cholangiocarcinoma complicating primary sclerosing cholangitis: cholangiographic appearances. Radiology 1985;156:43-46.

258. MacMAHON, HE, THANNHAUSER, SJ. Xanthomatous biliary cirrhosis; a clinical syndrome. Ann Intern Med 1949; 30:121.

259. MacQuillan GC, Neuberger J. Liver transplantation for primary biliary cirrhosis. Clin Liver Dis 2003;7:941-956.

260. Manns MP, Bremm A, Schneider PM, Notghi A, Gerken G, Prager-Eberle M, Stradmann-Bellinghausen B, Meyer zum Buschenfelde KH, Rittner C: HLA DRw8 and complement C4 deficiency as risk factors in primary biliary cirrhosis. Gastroenterology 1991, 101:1367-1373.

261. Manns MP., A.J.Czaja,J.D.Gorhametal.,"Diagnosis and management of autoimmune hepatitis," Hepatology, vol. 51,no. 6, pp. 2193–2213, 2010.

262. Marchesa, P, Lashner, BA, Lavery, IC, et al. The risk of cancer and dysplasia among ulcerative colitis patients with primary sclerosing cholangitis. Am J Gastroenterol 1997; 92:1285.

263. Markus, BH, Dickson, ER, Grambsch, PM, et al. Efficiency of liver transplantation in patients with primary biliary cirrhosis. N Engl J Med 1989; 320:1709.

264. Mason, AL, Farr, GH, Xu, L, et al. Pilot studies of single and combination antiretroviral therapy in patients with primary biliary cirrhosis. Am J Gastroenterol 2004; 99:2348.

265. Mathis KL,Dozois EJ, LarsonDW, Cima RR, Sarmiento JM,Wolff BG,et al. Ileal pouch-anal anastomosis and liver transplantation for ulcerativecolitis complicated by primary sclerosing cholangitis. Br J Surg 2008;95:882-886.

266. Matsuzaki Y, Tanaka N, Osuga T, et al. Improvement of biliary enzyme levels and itching as a result of long-term administration of ursodeoxycholic acid in primary biliary cirrhosis. Am J Gastroenterol 1990; 85:15.

267. Mayo MJ, Mosby JM, Jeyarajah R, Combes B, Khilnani S, Al-halimi M, et al. The relationship between hepatic immunoglobulin production and CD154 expression in chronic liverdiseases. Liver Int 2006;26(2):187–196

268. Mazzella, G, Parini, P, Bazzoli, F, et al. Ursodeoxycholic acid administration on bile acid metabolism in patients with early stages of primary biliary cirrhosis. Dig Dis Sci 1993; 38:896.

269. McFarlane IG. Autoimmune hepatitis: Clinical manifestations anddiagnostic criteria. Can J Gastroenterol 2001;15:107-113.

270. Mehal WZ, Lo YM, Wordsworth BP, Neuberger JM, Hubscher SC, Fleming KA, Chapman RW. HLA DR4 is a marker for rapid disease progression in primary sclerosing cholangitis. Gastroenterology 1994; 106: 160-167

271. Mella JG, Roschmann E, Maier KP, Volk BA: Association of primary biliary cirrhosis with the allele HLA-DPB1*0301 in a German population.Hepatology 1995, 21:398-402.

272. Mendes, FD, Jorgensen, R, Keach, J, et al. Elevated serum IgG4 concentration in patients with primary sclerosing cholangitis. Am J Gastroenterol 2006; 101:2070.

273. Menon, KV, Angulo, P, Weston, S, et al. Bone disease in primary biliary cirrhosis: independent indicators and rate of progression. J Hepatol 2001; 35:316.

274. Mieli-Vergani G, Vergani D. De novo autoimmune hepatitis after liver transplantation. J Hepatol 2004;40(1):3–7

275. Migliaccio, C, Van de Water, J, Ansari, AA, et al. Heterogeneous response of antimitochondrial autoantibodies and bile duct apical staining monoclonal antibodies to pyruvate dehydrogenase complex E2: the molecule versus the mimic. Hepatology 2001; 33:792.

276. Miller, LC, Kaplan, MM. Serum interleukin-2 and tumor necrosis factor-alpha in primary biliary cirrhosis: decrease by colchicine and relationship to HLA-DR4. Am J Gastroenterol 1992; 87:465.

277. Mitchison HC, Palmer JM, Bassendine MF, Watson AJ, Record CO, James OF. A controlled trial of prednisolone treatment in primary biliary cirrhosis: three-year results. J Hepatol 1992;15:336-344.

278. Miyake T, Miyaoka H, Abe M, Furukawa S, Shigematsu S,Furukawa E, et al. Clinical characteristics of autoimmune hepatitis in older aged patients. Hepatol Res 2006;36(2):139–142

279. Miyake Y.,Y.Iwasaki,H.Kobashietal.,"Clinicalfeaturesofautoimmune hepatitis diagnosed based on simplified criteriaof the International Autoimmune Hepatitis Group," Digestiveand Liver Disease, vol. 42, no. 3, pp. 210–215, 2010.

280. Miyoshi H, Uchida K, Taniguchi T et al (2008) Circulating Naïve and CD4+CD25 high regulatory T cells in patients withautoi-*-mmune pancreatitis. Pancreas 36:133–140

281. Montano Loza AJ, Czaja AJ. Current therapy for autoimmune hepatitis. Nat Clin Pract Gastroenterol Hepatol 2007;4:202-214.

282. Montano-Loza A, Czaja AJ, Carpenter HA, Piette A, Murphy D,Shums Z, et al. Frequency and significance of antibodies tocyclic citrullinated peptide in type 1 autoimmune hepatitis.Autoimmunity 2006;39(4):341–348

283. Montano-Loza AJ, Carpenter HA, Czaja AJ. Improving the end point of corticosteroid therapy in type 1 autoimmune hepatitis to reduce the frequency of relapse. Am J Gastroenterol 2007; 102:1005.

284. Montano-Loza AJ, Carpenter HA, Czaja AJ. Predictive factors for hepatocellular carcinoma in type 1 autoimmune hepatitis. Am J Gastro-enterol 2008;103:1944-1951.

285. Moon SH, Kim MH, Park DH, et al. IgG4 immunostaining of duodenal papillarybiopsy specimens may be useful for supporting a diagnosis of autoimmunepancreatitis. Gastrointest Endosc 2010; 71:960–966.

286. Moreno Luna LE, Kipp B, Halling KC, Sebo TJ, Kremers WK, RobertsLR, et al. Advanced cytologic techniques for the detection of malignantpancreatobiliary strictures. Gastroenterology 2006;131:1064-1072.

287. MoritokiY,LianZX,OhsugiY,UenoY,GershwinME.Bcells andAutoimmune liver diseases. Autoimmun Rev 2006;5(7):449–457

288. Mullarkey ME, Stevens AM, McDonnell WM, Loubiere LS, Brackensick JA, Pang JM, Porter AJ, Galloway DA, Nelson JL: Human leukocyte antigen class II alleles in Caucasian women with primary biliary cirrhosis. Tissue Antigens 2005, 65:199-205.

289. Muratori P, Granito A, Quarneti C, et al. Autoimmune hepatitis in Italy: the Bologna experience. J Hepatol 2009; 50:1210.

290. Muratori, L, Granito, A, Muratori, P, et al. Antimitochondrial antibodies and other antibodies in primary biliary cirrhosis: diagnostic and prognostic value. Clin Liver Dis 2008; 12:261.

291. Muratori, L, Sztul, E, Muratori, P, et al. Distinct epitopes on formiminotransferase cyclodeaminase induce autoimmune liver cytosol antibody type 1. Hepatology 2001; 34:494.

292. Murphy GM, Ross A, Billing BH. Serum bile acids in primary biliary cirrhosis. Gut 1972; 13:201.

293. Nakamura K, M. Yoneda, S. Yokohama et al., “Efficacyof ursodeoxycholic acid in Japanese patients with typeautoimmune hepatitis,” Journal of Gastroenterology andHepatology, vol. 13, no. 5, pp. 457–495, 1998.

294. Nakamura, M, Kondo, H, Mori, T, et al. Anti-gp210 and anti-centromere antibodies are different risk factors for the progression of primary biliary cirrhosis. Hepatology 2007; 45:118.

295. Nakanuma, Y, Ohta, G. Nodular hyperplasia of the liver in primary biliary cirrhosis of early histological stages. Am J Gastroenterol 1987; 82:8.

296. Nakazawa, T, Ohara, H, Sano, H, et al. Cholangiography can discriminate sclerosing cholangitis with autoimmune pancreatitis from primary sclerosing cholangitis. Gastrointest Endosc 2004; 60:937.

297. Neuberger, J. Recurrent primary biliary cirrhosis. Liver Transpl 2003; 9:539.

298. Newton, JL, Davidson, A, Kerr, S, et al. Autonomic dysfunction in primary biliary cirrhosis correlates with fatigue severity. Eur J Gastroenterol Hepatol 2007; 19:125.

299. Olsson, R, Boberg, KM, de Muckadell, OS, et al. High-dose ursodeoxycholic acid in primary sclerosing cholangitis: a 5-year multicenter, randomized, controlled study. Gastroenterology 2005; 129:1464

300. Nilsson HO, Taneera J, Castedal M, Glatz E, Olsson R, Wadstrom T. Identification of Helicobacter pylori and other Helicobacter species by PCR, hybridization, and partial DNA sequencing in human liver samples from patients withprimary sclerosing cholangitis or primary biliary cirrhosis. J Clin Microbiol 2000; 38: 1072-1076

301. Niro GA, Poli F, Andriulli A, Bianchi I, Bernuzzi F, Caliari L, et al. TNF-alpha polymorphisms in primary biliary cirrhosis: a northen and southern Italian experience. Ann N Y Acad Sci. Sep 2009; 1173:557-63.

302. Nishi H, Tojo A, Onozato ML, Jimbo R, Nangaku M, Uozaki H,Hirano K et al (2007) Anti-carbonic anhydrase II antibody inautoimmune pancreatitis and tubulointerstitial nephritis. NephrolDial Transplant 22:1273–5

303. Nishimori I, Tamakoshi A, Otsuki M. Prevalence of autoimmune pancreatitis in Japan from a nationwide survey in 2002. *J. Gastroenterol.* 42(Suppl. 18),6-8 (2007).

304. Nishino T, Toki F, Oyama H, et al. Long-term outcome of autoimmune pancreatitis after oral prednisolone therapy. Intern Med 2006; 45:497–501.

305. Norris S, Kondeatis E, Collins R, Satsangi J, Clare M, Chapman R, Stephens H, Har r i son P, Vaughan R, Donaldson P. Mapping MHC-encoded susceptibility and resistance in primary sclerosing cholangitis: the role of MICA polymorphism. Gastroenterology 2001; 120: 1475-1482

306. Obermayer-Straub P, J. Perheentupa, S. Braun et al.,"Hepatic autoantigens in patients with autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy,"Gastroenterology, vol. 121, no. 3, pp. 668–677, 2001.

307. O'Brien, C, Joshi, S, Feld, JJ, et al. Long-term follow-up of antimitochondrial antibody-positive autoimmune hepatitis. Hepatology 2008; 48:550.

308. Ochsenkühn, T, Bayerdörffer, E, Meining, A, et al. Colonic mucosal proliferation is related to serum deoxycholic acid levels. Cancer 1999; 85:1664.

309. Oertelt, S, Rieger, R, Selmi, C, et al. A sensitive bead assay for antimitochondrial antibodies: Chipping away at AMA-negative primary biliary cirrhosis. Hepatology 2007; 45:659.

310. Okazaki K (2006) In: Pour Parviz M (ed) Autoimmune pancreatitis—recent concept. Target organ toxicology series, toxicology of thepancreas. Taylor & Francis, Boca Raton, pp 459–473

311. Okazaki K, Kawa S, Kamisawa T, Naruse S, Tanaka S, NishimoriI et al (2006) Clinical diagnostic criteria of autoimmunepancreatitis: revised proposal. J Gastroenterol 41:626–31

312. Okazaki K, Uchida K, Chiba T (2001) Recent concept ofautoimmune-related pancreatitis. J Gastroenterol 36:293–302

313. Okazaki K, Uchida K, Ohana M et al (2000) Autoimmune-related pancreatitis is associated with autoantibodies and Th1/Th2-typecellular immune response. Gastroenterology 118:573–581

314. Okazaki, K. Autoimmune pancreatitis is increasing in Japan. Gastroenterology 2003; 125:1557.

315. Okazaki K, Kawa S, Kamisawa T, et al. Japanese clinical guidelines forautoimmune pancreatitis. Pancreas 2009; 38:849–866. This is a comprehensive publication of the Japanese experience with AIP. Itemploys a novel strategy called the modified Delphi method to build consensus.It combines the available evidence and experience for the diagnosis and treatmentof AIP.

316. Olsson R, Bjornsson E, Backman L, Friman S, Hockerstedt K,Kaijser B, Olausson M. Bile duct bacterial isolates in primary sclerosing cholangitis: a study of explanted livers. J Hepatol 1998; 28: 426-432.

317. Olsson, R, Boberg, KM, de Muckadell, OS, et al. High-dose ursodeoxycholic acid in primary sclerosing cholangitis: a 5-year multicenter, randomized, controlled study. Gastroenterology 2005; 129:1464

318. O'Mahony CA, Vierling JM. Etiopathogenesis of primary sclerosing cholangitis. Semin Liver Dis 2006; 26: 3-21

319. M. Ota, T. Seki, K. Kiyosawa et al., “A possible association between basic amino acids of position 13 of DRB1 chains and autoimmune hepatitis,” Immunogenetics, vol. 36, no. 1, pp.49–55, 1992.

320. Otsuki M, Chung JB, Okazaki K, Kim MH, Kamisawa T, Kawa Set al (2008) Asian diagnostic criteria for autoimmune pancreatitis:consensus of the Japan–Korea Symposium on AutoimmunePancreatitis. J Gastroenterol 43:403–408

321. Oukka M (2007) Interplay between pathogenic Th17 andregulatory T cells. Ann Rheum Dis 66(Suppl 3):iii87–90

322. Palmer, JM, Yeaman, SJ, Bassendine, MF, James, OF. M4 and M9 autoantigens in primary biliary cirrhosis--a negative study. J Hepatol 1993; 18:251.

323. Pannala R, Chari ST. Corticosteroid treatment for autoimmune pancreatitis.Gut 2009; 58:1438–1439.

324. Pardi DS, Loftus EV Jr, KremersWK, Keach J, Lindor KD. Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitisand primary sclerosing cholangitis.Gastroenterology 2003;124:889-893.

325. Parham, Peter (2005). *The immune system*. New York: Garland Science. pp. 344. ISBN 0-8153-4093-1

326. Park DH, Kim M-H, Chari ST. Recent advances in autoimmune pancreatitis. *Gut* DOI: gut.2008.155853v1 (2009) (Epub ahead of print).

327. Park DH, Kim MH, Chari ST. Recent advances in autoimmune pancreatitis.Gut 2009; 58:1680–1689.

328. Park do H, Kim MH, Oh HB *et al*. Substitution of aspartic acid at position 57 of the DQß1 affects relapse of autoimmune pancreatitis. *Gastroenterology* 134(2),440-446 (2008).

329. Parlak E, Kuran SO, Disibeyaz S, Ciçek B, Oguz D, Sahin B. Endoscopic treatment of primary sclerosing cholangitis. Turk J Gastroenterol. 2004;15:144-148. Abstract

330. Pawlik, TM, Olbrecht, VA, Pitt, HA, et al. Primary sclerosing cholangitis: role of extrahepatic biliary resection. J Am Coll Surg 2008; 206:822.

331. Phillips, JR, Angulo, P, Petterson, T, Lindor, KD. Fat-soluble vitamin levels in patients with primary biliary cirrhosis. Am J Gastroenterol 2001; 96:2745.

332. Pohl J, Ring A, Stremmel W, Stiehl A. The role of dominant stenoses in bacterial infections of bile ducts in primary sclerosing cholangitis. Eur J Gastroenterol Hepatol2006;18:69-74.

333. Pokorny CS, Norton ID, McCaughan GW, Selby WS. Anti-neutrophil cytoplasmic antibody: a prognostic indicator in primary sclerosing cholangitis. J Gastroenterol Hepatol 1994; 9: 40-44

334. Ponsioen CY, Vrouenraets SM, PrawirodirdjoW, RajaramR, Rauws EA,Mulder CJ, et al. Natural history of primary sclerosing cholangitis andprognostic value of cholangiography in a Dutch population. Gut 2002;51:562-566.

335. Portmann, B, Popper, H, Neuberger, J, Williams, R. Sequential and diagnostic features in primary biliary cirrhosis based on serial histologic study in 209 patients. Gastroenterology 1985; 88:1777.

336. Poupon R. Primary biliary cirrhosis: a 2010 update. J Hepatol 52:745-758, 2010.

337. Poupon, R, Chazouilleres, O, Corpechot, C, Chrétien, Y. Development of autoimmune hepatitis in patients with typical primary biliary cirrhosis. Hepatology 2006; 44:85.

338. Poupon, RE, Balkau, B, Guéchot, J, Heintzmann, F. Predictive factors in ursodeoxycholic acid-treated patients with primary biliary cirrhosis: role of serum markers of connective tissue. Hepatology 1994; 19:635.

339. Pratt DS, Flavin DP, Kaplan MM. The successful treatment of autoimmune hepatitis with 6-mercaptopurine after failure with azathioprine. Gastroenterology 1996; 110:271.

340. Prince, MI, Chetwynd, A, Craig, WL, et al. Asymptomatic primary biliary cirrhosis: clinical features, prognosis, and symptom progression in a large population based cohort. Gut 2004; 53:865.

341. Prochazka, EJ, Terasaki, PI, Park, MS, et al. Association of primary sclerosing cholangitis with HLA-DRw52a. N Engl J Med 1990; 322:1842.

342. Propst, A, Propst, T, Lechleitner, M, et al. Hypercholesterolemia in primary biliary cirrhosis is no risk factor for atherosclerosis. Dig Dis Sci 1993; 38:379.

343. Prytz H, Keiding S, Björnsson E, et al. Dynamic FDG-PET is useful for detection of cholangiocarcinoma in patients with PSC listed for liver transplantation. Hepatology 2006; 44:1572.

344. Raina, A, Krasinskas, AM, Greer, JB, et al. Serum immunoglobulin G fraction 4 levels in pancreatic cancer: elevations not associated with autoimmune pancreatitis. Arch Pathol Lab Med 2008; 132:48.

345. Raina, A, Yadav, D, Krasinskas, AM, et al. Evaluation and management of autoimmune pancreatitis: experience at a large US center. Am J Gastroenterol 2009; 104:2295.

346. Rasmussen, HH, Fallingborg, JF, Mortensen, PB, et al. Hepatobiliary dysfunction and primary sclerosing cholangitis in patients with Crohn's disease. Scand J Gastroenterol 1997; 32:604.

347. Rautiainen, H, Kärkkäinen, P, Karvonen, AL, et al. Budesonide combined with UDCA to improve liver histology in primary biliary cirrhosis: a three-year randomized trial. Hepatology 2005; 41:747.

348. Rigopoulou EI, Davies ET, Bogdanos DP, Liaskos C, Mytilinaiou M, Koukoulis GK, Dalekos GN, Vergani D. Antimitochondrial antibodies of immunoglobulin G3 subclassare associated with a more severe disease course in primary biliary cirrhosis.Liver Int 2007; 27:1226-1231

349. Roberts SK, Therneau TM, Czaja AJ. Prognosis of histological cirrhosis in type 1 autoimmune hepatitis. Gastroenterology 1996;110:848-857.

350. Rodrigues CM, Fan G, Ma X, Kren BT, Steer CJ. A novel role for ursodeoxycholic acid in inhibiting apoptosis by modulating mitochondrial membrane perturbation.J Clin Invest. 1998; 101:2790-2799.(pubmed:9637713)

351. Rosen, CB, Nagorney, DM, Wiesner, RH, et al. Cholangiocarcinoma complicating primary sclerosing cholangitis. Ann Surg 1991; 213:21.

352. Rosen, H. Primary biliary cirrhosis and bone disease. Hepatology 1995; 21:253.

353. Rowe IA, Webb K, Gunson BK, Mehta N, Haque S, Neuberger J. Theimpact of disease recurrence on graft survival following liver transplantation: a single centre experience. Transpl Int 2008;21:459-465.

354. Rudolph G, Gotthardt D, Kloters-Plachky P, Kulaksiz H, Rost D, StiehlA. Influence of dominant bile duct stenoses and biliary infections onoutcome in primary sclerosing cholangitis. J Hepatol 2009;51:149-155.

355. Rudolph, G, Gotthardt, D, Kloeters-Plachky, P, et al. In PSC with dominant bile duct stenosis, IBD is associated with an increase of carcinomas and reduced survival. J Hepatol 2010; 53:313.

356. Rueda, JC, Duarte-Rey, C, Casas, N. Successful treatment of relapsing autoimmune pancreatitis in primary Sjögren's syndrome with rituximab: report of a case and review of the literature. Rheumatol Int 2009; 29:1481.

357. Rust C, Beuers U. Overlap syndromes among autoimmune liver diseases. World J Gastroenterol 2008; 14:3368.

358. Sacher M, Blümel P, Thaler H, Manns M. Chronic active hepatitis associated with vitiligo, nail dystrophy, alopecia and a new variant of LKM antibodies. J Hepatol 1990; 10:364.

359. Saftoiu A, Vilmann P, Gorunescu F *et al.* Neural network analysis of dynamic sequences of EUS elastography used for the differential diagnosis of chronic pancreatitis and pancreatic cancer. *Gastrointest. Endosc.*68(6),1086-1094 (2008).

360. Sah, RP, Chari, ST, Pannala, R, et al. Differences in clinical profile and relapse rate of type 1 versus type 2 autoimmune pancreatitis. Gastroenterology 2010; 139:140.

361. Sahani DV, Kalva SP, Farrell J *et al.* Autoimmune pancreatitis: imaging features. *Radiology* 233(2),345-352 (2004).

362. Sahani, DV, Sainani, NI, Deshpande, V, et al. Autoimmune pancreatitis: disease evolution, staging, response assessment, and CT features that predict response to corticosteroid therapy. Radiology 2009; 250:118.

363. Saich R, Chapman R. Primary sclerosing cholangitis, autoimmune hepatitis and

364. Said K, Glaumann H, Bergquist A. Gallbladder disease in patients withprimary sclerosing cholangitis. J Hepatol 2008;48:598-605.

365. Sakaguchi S. Naturally arising Foxp3-expressing CD25?CD4? regulatory T cells in immunological tolerance to self and non-self. Nat Immunol 2005;6(4):345–352

366. Sanchez-Urdazpal L, Czaja AJ, van Hoek B, et al. Prognostic features and role of liver transplantation in severe corticosteroid-treated autoimmune chronic active hepatitis. Hepatology 1992; 15:215.

367. Sandanayake, NS, Church, NI, Chapman, MH, et al. Presentation and management of post-treatment relapse in autoimmune pancreatitis/immunoglobulin G4-associated cholangitis. Clin Gastroenterol Hepatol 2009; 7:1089.

368. Satsangi J, Chapman RW, Haldar N, Donaldson P, Mitchell S, Simmons J, Norris S, Marshall SE, Bell JI, Jewell DP, Welsh KI. A functional polymorphism of the stromelysin gene (MMP-3) inf luences suscept ibi l i ty to primary sclerosing cholangitis. Gastroenterology 2001; 121: 124-130

369. Schaffner, F. Paradoxical elevation of serum cholesterol by clofibrate in patients with primary biliary cirrhosis. Gastroenterology 1969; 57:253.

370. Scheuer PJ. Ludwig Symposium on biliary disorders--part II. Pathologic features and evolution of primary biliary cirrhosis and primary sclerosing cholangitis. Mayo Clin Proc 1998; 73: 179-183

371. Scheuer P. Primary biliary cirrhosis.*Proc R Soc Med.* Dec1967;60(12):1257-60

372. Schramm C, Herkel J, Beuers U, Kanzler S, Galle PR, Lohse AW. Pregnancy in autoimmune hepatitis: outcome and risk factors. Am J Gastroenterol 2006;101(3):556–560

373. Schrumpf E, Abdelnoor M, Fausa O, Elgjo K, Jenssen E,Kolmannskog F. Risk factors in primary sclerosingcholangitis. J Hepatol 1994;21:1061-1066.

374. Schussler, GC, Schaffner, F, Korn, F. Increased serum thyroid hormone binding and decreased free hormone in chronic active liver disease. N Engl J Med 1978; 299:510.

375. Seaberg EC, Belle SH, Beringer KC, Schivins JL, Detre KM. Livertransplantation in the United States from 1987-1998: updated results from the Pitt-UNOS liver transplant registry. In: Cecka JM,Terasaki PI, eds. Clinical Transplants 1998 . Los Angeles: UCLA Tissue Typing Laboratories 1999: 17-37.

376. Selmi C, Invernizzi P, Keefe EB, Coppel RL, Podda M, Rossaro L, Ansari AA, Gershwin ME: Epidemiology and pathogenesis of primary biliary cirrhosis. J Clin Gastroenterol 2004, 38:264-271.

377. Selmi, C, Ross, SR, Ansari, AA, et al. Lack of immunological or molecular evidence for a role of mouse mammary tumor retrovirus in primary biliary cirrhosis. Gastroenterology 2004; 127:493.

378. Sheth, SG, Bishop, MD, Shea, JC, et al. Association of primary sclerosing cholangitis (PSC) with the cystic fibrosis carrier state: Results of extensive genotypic and phenotypic analysis (abstract). Gastroenterology 2001; 120:A75.

379. Shetty, K, Rybicki, L, Brzezinski, A, et al. The risk for cancer or dysplasia in ulcerative colitis patients with primary sclerosing cholangitis. Am J Gastroenterol 1999; 94:1643.

380. Shi, J, Li, Z, Zeng, X, et al. Ursodeoxycholic acid in primary sclerosing cholangitis: meta-analysis of randomized controlled trials. Hepatol Res 2009; 39:865.

381. Shimoda S, Harada K, Niiro H, Yoshizumi T, Soejima Y, Taketomi A, Maehara Y, Tsuneyama K, Nakamura M, Komori A, Migita K, Nakanuma Y, Ishibashi H, Selmi C, Gershwin ME: Biliary epithelial cells and primary biliary cirrhosis: The role of liver-infiltrating mononuclear cells. Hepatology 2008, 47:958-965

382. Shimoda, S, Van de Water, J, Ansari, A, et al. Identification and precursor frequency analysis of a common T cell epitope motif in mitochondrial autoantigens in primary biliary cirrhosis. J Clin Invest 1998; 102:1831.

383. Siegel, JL, Jorgensen, R, Angulo, P, Lindor, KD. Treatment with ursodeoxycholic acid is associated with weight gain in patients with primary biliary cirrhosis. J Clin Gastroenterol 2003; 37:183.

384. Slapak, GI, Saxena, R, Portmann, B, et al. Graft and systemic disease in long-term survivors of liver transplantation. Hepatology 1997; 25:195.

385. Soetikno, RM, Lin, OS, Heidenreich, PA, et al. Increased risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis: a meta-analysis. Gastrointest Endosc 2002; 56:48.

386. Solano E, Khakhar A, Bloch M, et al. Liver transplantation for primary sclerosing cholangitis. Transplant Proc. 2003;35:2431-2434. Abstract

387. Sorokin, A, Brown, JL, Thompson, PD. Primary biliary cirrhosis, hyperlipidemia, and atherosclerotic risk: A systematic review. Atherosclerosis 2007; 46:776.

388. Springer, J, Cauch-Dudek, K, O'Rourke, K, et al. Asymptomatic primary biliary cirrhosis: a study of its natural history and prognosis. Am J Gastroenterol 1999; 94:47.

389. Springer, JE, Cole, DE, Rubin, LA, et al. Vitamin D-receptor genotypes as independent genetic predictors of decreased bone mineral density in primary biliary cirrhosis. Gastroenterology 2000; 118:145.

390. Spurkland A, Saarinen S, Boberg KM, Mitchell S, Broome U, Caballeria L, Ciusani E, Chapman R, Ercilla G, Fausa O, Knutsen I, Pares A, Rosina F, Olerup O, Thorsby E, Schrumpf E. HLA class II haplotypes in primary sclerosing cholangitis patients from five European populations. Tissue Antigens 1999; 53: 459-469

391. Stahlberg D, Veress B, Tribukait B, Broome U. Atrophy and neoplastictransformation of the ileal pouch mucosa in patients with ulcerative colitis and primary sclerosing cholangitis: a case control study. Dis ColonRectum 2003;46:770-778.

392. Stellaard F, Bolt MG, Boyer JL, Klein PD. Phenobarbital treatment in primary biliary cirrhosis. Differences in bile acid composition between responders and nonresponders. J Lab Clin Med 1979; 94:853.

393. Stellon AJ, Hegarty JE, Portmann B, Williams R. Randomized controlled trial of azathioprine withdrawal in autoimmune chronic active hepatitis. *Lancet*. 1985; 1: 668-70.

394. Stiehl A, Rudolph G, Sauer P, et al. Efficacy of ursodeoxycholic acid treatment and endoscopic dilation of major duct stenoses in primary sclerosing cholangitis. An 8-year prospective study. J Hepatol. 1997;26:560-566. Abstract

395. Stiehl A. Primary sclerosing cholangitis: the role of endoscopic therapy. Semin Liver Dis. 2006;26:62-68. Abstract

396. Stiehl, A, Rudolph, G, Klöters-Plachky, P, et al. Development of dominant bile duct stenoses in patients with primary sclerosing cholangitis treated with ursodeoxycholic acid: outcome after endoscopic treatment. J Hepatol 2002; 36:151.

397. Su, TC, Hwang, JJ, Kao, JH. Hypercholesterolemia in primary biliary cirrhosis. N Engl J Med 2007; 357:1561.

398. Suarez, CR, Pickett, WC, Bell, DH, et al. Effect of low dose methotrexate on neutrophil chemotaxis induced by leukotriene B4 and complement C5a. J Rheumatol 1987; 14:9.

399. Sugumar A, Chari S. Autoimmune pancreatitis: an update. Expert Rev Gastroenterol Hepatol 2009; 3:197–204.

400. Sugumar A, Kloppel G, Chari ST. Autoimmune pancreatitis: pathologic subtypes and their implications for its diagnosis. Am J Gastroenterol2009; 104:2308–2310. This editorial discusses the reasons for the geographical variations observed in AIP.

401. Sugumar A, Smyrk TC, Takahashi N, Levy MJ, Chari ST. Lymphoplasmacytic sclerosing pancreatitis (LPSP) and idiopathic duct centric pancreatis (IDCP) are distinct clinical forms of autoimmune pancreatitis (AIP).*Pancreas* 37(4),497-497 (2008).

402. Talwalkar JA, Souto E, Jorgensen RA, Lindor KD. Natural history of pruritus in primary biliary cirrhosis. Clin Gastroenterol Hepatol 2003; 1:297.

403. Tanaka A, Nezu S, Uegaki S, Mikami M, Okuyama S, Kawamura N, Aiso M, Gershwin ME, Takahashi S, Selmi C, Takikawa H. The clinical significance of IgA antimitochondrial antibodies in sera and saliva in primary biliary cirrhosis. Ann N Y Acad Sci 2007; 1107: 259-270

404. Tandon P, Rowe BH, Vandermeer B, Bain VG. The efficacy and safety of bile Acid binding agents, opioid antagonists, or rifampin in the treatment of cholestasis-associated pruritus. Am J Gastroenterol 2007; 102:1528.

405. Terasaki, S, Nakanuma, Y, Yamazaki, M, Unoura, M. Eosinophilic infiltration of the liver in primary biliary cirrhosis: a morphological study. Hepatology 1993; 17:206.

406. Terg R, Coronel E, Sordá J, et al. Efficacy and safety of oral naltrexone treatment for pruritus of cholestasis, a crossover, double blind, placebo-controlled study. J Hepatol 2002; 37:717.

407. Terjung, B, Spengler, U, Sauerbruch, T, Worman, HJ. "Atypical p-ANCA" in IBD and hepatobiliary disorders react with a 50-kilodalton nuclear envelope protein of neutrophils and myeloid cell lines. Gastroenterology 2000; 119:310.

408. Terrabuio DR, Abrantes-Lemos CP, Carrilho FJ, Cancado EL.Follow-up of pregnant women with autoimmune hepatitis: the disease behavior along with maternal and fetal outcomes. J Clin Gastroenterol 2009;43(4):350–356

409. Thornton JR, Losowsky MS. Plasma leucine enkephalin is increased in liver disease. Gut 1989; 30:1392.

410. Tischendorf JJ, Hecker H, KrugerM,MannsMP,Meier PN. Characterization, outcome, and prognosis in 273 patients with primary sclerosingcholangitis: A single center study. Am J Gastroenterol 2007;102:107-114.

411. Topazian, M, Witzig, TE, Smyrk, TC, et al. Rituximab therapy for refractory biliary strictures in immunoglobulin G4-associated cholangitis. Clin Gastroenterol Hepatol 2008; 6:364.

412. Treichel, U, McFarlane, BM, Seki, T, et al. Demographics of anti-asialoglycoprotein receptor autoantibodies in autoimmune hepatitis. Gastroenterology 1994; 107:799.

413. Tsuneyama, K, Van de Water, J, Leung, PS, et al. Abnormal expression of the E2 component of the pyruvate dehydrogenase complex on the luminal surface of biliary epithelium occurs before major histocompatibility complex class II and BB1/B7 expression. Hepatology 1995; 21:1031.

414. Turnberg, LA, Mahoney, MP, Gleeson, MH, et al. Plasmaphoresis and plasma exchange in the treatment of hyperlipaemia and xanthomatous neuropathy in patients with primary biliary cirrhosis. Gut 1972; 13:976.

415. Uchida K, Okazaki K, Konishi Y et al (2000) Clinical analysis ofautoimmune-related pancreatitis. Am J Gastroenterol 95:2788–2794

416. Umemura T, Ota M, Hamano H et al (2006) Genetic associationof Fc receptor-like 3 polymorphisms with autoimmune pancreatitis in Japanese patients. Gut 55:1367–1368

417. Umemura T, Ota M, Hamano H, Katsuyama Y, Muraki T, ArakuraN, Kawa S, Kiyosawa K (2008) Association of autoimmunepancreatitis with cytotoxic T-lymphocyte antigen 4 gene polymorphisms in Japanese patients. Am J Gastroenterol 103:588–94

418. Van de Water, J, Ansari, A, Prindiville, T, et al. Heterogeneity of autoreactive T cell clones specific for the E2 component of the pyruvate dehydrogenase complex in primary biliary cirrhosis. J Exp Med 1995; 181:723.

419. Van de Water, J, Turchany, J, Leung, PS, et al. Molecular mimicry in primary biliary cirrhosis. Evidence for biliary epithelial expression of a molecule cross-reactive with pyruvate dehydrogenase complex-E2. J Clin Invest 1993; 91:2653.

420. van Milligen de Wit, AW, van Deventer, SJ, Tytgat, GN. Immunogenetic aspects of primary sclerosing cholangitis: implications for therapeutic strategies. Am J Gastroenterol 1995; 90:893.

421. Vergani D., G. Mieli-Vergani, M. Mondelli, B. Portmann, andA. L. W. F. Eddleston, “Immunoglobulin on the surface ofisolated hepatocytes is associated with antibody-dependentcell-

mediated cytotoxicity and liver damage," Liver,vol.7,no.6, pp. 307–315, 1987.

422. Verma S, Torbenson M, Thuluvath PJ. The impact of ethnicity on the natural history of autoimmune hepatitis. Hepatology 2007; 46:1828.

423. Vogel A, Heinrich E, Bahr MJ, Rifai K, Flemming P, Melter M, et al.Long-term outcome of liver transplantation for autoimmune hepatitis.Clin Transplant 2004;18:62-69

424. Vuoristo M, Farkkila M, Karvonen AL, et al. A placebo-controlled trial of primary biliary cirrhosis treatment with colchicine and ursodeoxycholic acid. Gastroenterology 1995;108:1470-1478.

425. Wächter, B, Kyriatsoulis, A, Lohse, AW, et al. Characterization of liver cytokeratin as a major target antigen of anti-SLA antibodies. J Hepatol 1990; 11:232.

426. Wagner S, Gebel M, Meier P, et al. Endoscopic management of biliary tract strictures in primary sclerosing cholangitis. Endoscopy. 1996;28:546-551. Abstract

427. Wakabayashi T, Kawaura Y, Satomura Y, Watanabe H, Motoo Y, Sawabu N. Long-term prognosis of duct-narrowing chronic pancreatitis: strategy for steroid treatment. Pancreas 2005;30:31-39.

428. Wang KK, Czaja AJ, Beaver SJ, Go VL. Extrahepatic malignancy following long-term immunosuppressive therapy of severe hepatitis Bsurface antigen-negative chronic active hepatitis. HEPATOLOGY 1989;10:39-43

429. Watt, FE, James, OF, Jones, DE. Patterns of autoimmunity in primary biliary cirrhosis patients and their families: a population-based cohort study. QJM 2004; 97:397.

430. Wee, A, Ludwig, J. Pericholangitis in chronic ulcerative colitis: primary sclerosing cholangitis of the small bile ducts? Ann Intern Med 1985; 102:581.

431. Wen L, Ma Y, Bogdanos DP, Wong FS, Demaine A, Mieli-Vergani G, Vergani D. Pediatric autoimmune liver diseases: the molecular basis of humoral and cellular immunity. Curr Mol Med 2001; 1: 379-389

432. Wen L, Peakman M, Lobo-Yeo A, McFarlane BM, Mowat AP, Mieli-Vergani G, Vergani D. T-cell-directed hepatocyte damage in autoimmune chronic active hepatitis. Lancet 1990; 336: 1527-1530

433. Werner M, Wallerstedt S, Lindgren S, *et al*. Characteristic and long-term outcome of patients with autoimmune hepatitis related to the initial treatment response. Scand J Gastroenterol 2010; 45; 457-467.

434. Wesierska-Gadek J, Penner E, Battezzati PM, Selmi C, Zuin M, Hitchman E, Worman HJ, Gershwin ME, Podda M, Invernizzi P: Correlation of initial autoantibody profile and clinical outcome in primary biliary cirrhosis. Hepatology 2006, 43:1135-1144.

435. Wiegand J, Schuler A, Kanzler S, Lohse A, Beuers U, KreiselW, et al. Budesonide in previously untreated autoimmune hepatitis. Liver Int 2005;25(5):927–934

436. Wiencke K, Louka AS, Spurkland A, Vatn M, Schrumpf E, Boberg KM. Association of matrix metalloproteinase-1 and -3 promoter polymorphisms with clinical subsets of Norwegian primary sclerosing cholangitis patients. J Hepatol 2004; 41: 209-214

437. Wiesner, RH. Current concepts in primary sclerosing cholangitis. Mayo Clin Proc 1994; 69:969.

438. WojcickiM,Milkiewicz P, SilvaM. Biliary tract complications after livertransplantation: a review. Dig Surg 2008;25:245-257.

439. Woolf, GM, Vierling, JM. Disappearing intrahepatic bile ducts: the syndromes and their mechanisms. Semin Liver Dis 1993; 13:261.

440. Worthington J, Cullen S, Chapman R. Immunopathogenesis of primary sclerosing cholangitis. Clin Rev AllergyImmunol 2005;28:93-103.

441. Xu B, Broome U, Ericzon BG, Sumitran-Holgersson S. High frequency of autoantibodies in patients with primary sclerosing cholangitis that bind biliary epithelial cells and induce expression of CD44 and production of interleukin 6. Gut 2002; 51: 120-127

442. Xu, L, Sakalian, M, Shen, Z, et al. Cloning the human betaretrovirus proviral genome from patients with primary biliary cirrhosis. Hepatology 2004; 39:151.

443. Yamazaki, K, Nakadate, I, Suzuki, K, et al. Eosinophilia in primary biliary cirrhosis. Am J Gastroenterol 1996; 91:516.

444. Yeoman AD, Al-Chalabi T, Karani JB, Quaglia A, Devlin J, Mieli-Vergani G, et al. Evaluation of risk factors in the development of hepatocellular carcinoma in autoimmune hepatitis: Implications for fol-low-up and screening. HEPATOLOGY 2008;48:863-870

445. Yoshida K, Toki F, Takeuchi T, et al. Chronic pancreatitis caused by an autoimmune abnormality. Proposal of the concept of autoimmune pancreatitis. Dig Dis Sci 1995; 40:1561–1568.

446. ZamboniG, Luttges J, Capelli P, et al. Histopathological features of diagnosticand clinical relevance in autoimmune pancreatitis: a study on 53 resectionspecimens and 9 biopsy specimens. Virchows Arch 2004; 445:552–563.

447. Zein, CO, Beatty, K, Post, AB, et al. Smoking and increased severity of hepatic fibrosis in primary biliary cirrhosis: A cross validated retrospective assessment. Hepatology 2006; 44:1564.

448. Zen Y, Fujii T, Harada K et al (2007) Th2 and regulatory immunereactions are increased in immunoglobin G4-related sclerosingpancreatitis and cholangitis. Hepatology 45:1538–46

449. Zhang L, Notohara K, Levy MJ, et al. IgG4-positive plasma cell infiltration in the diagnosis of autoimmune pancreatitis. Modpathol 2007;20:23-28.

450. Züchner, D, Sternsdorf, T, Szostecki, C, et al. Prevalence, kinetics, and therapeutic modulation of autoantibodies against Sp100 and promyelocytic leukemia protein in a large cohort of patients with primary biliary cirrhosis. Hepatology 1997; 26:1123.

451. Zauli, D, Ghetti, S, Grassi, A, et al. Anti-neutrophil cytoplasmic antibodies in type 1 and 2 autoimmune hepatitis. Hepatology 1997; 25:1105.